A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Inclusion criteria * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. Ability to understand and the willingness to sign a written informed consent. * Male or female aged = 18 years at the time of informed consent form (ICF) signature. * Patients with histological diagnosis of resectable colorectal Cancer (CRC), or radiographic/visual findings highly suggestive, with planned confirmatory biopsy. * CRC lesions must be at least 1 centimeter (cm) in largest diameter and amenable to endoscopic biopsy. * Patient must be willing and able to have endoscopic biopsy (Goal 3-6 core-needle or surgical/endoscopic biopsies, final number to be determined by the physician performing the procedure as safe) of tumor prior to initiation of therapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The exception will be patients with long term disability (such as cerebral palsy) that is unlikely to significantly affect their response to therapy. * Patient is determined to be a surgical candidate for resection of their tumor. * Adequate organ and marrow function as defined in the protocol. * Further inclusion criteria apply. Exclusion criteria * Patients who are deemed to be at high risk for colonic obstruction and/or perforation per investigator assessment. * Patients eligible for neoadjuvant therapy (chemotherapy, radiotherapy, chemoradiotherapy) as standard of care. * Major surgery (major according …